Health and Prostate

Buy non prescription drugs: Asacol, Diamox

In recent weeks, the FDA has approved two drugs for prostate cancer: Hoechst’s antiandrogen nilutamide (Nilandron) for metastatic disease and Immunex’ antineoplastic mitoxantrone (Novantrone) for hormone-resistant disease. Neither drug offers a cure for prostate cancer, but both delay disease progression and provide relief of bone pain.

Nilutamide

Nilutamide (Nilandron) is indicated for add-on therapy following surgical or chemical castration. The drug promotes disease regression, prolongs survival, and decreases bone pain. In one double-blind, randomized multicenter study comparing 225 castrated patients who received nilutamide and 232 castrated patients who received placebo, patients in the nilutamide group showed a longer progression-free survival (21.2 months in the nilutamide group versus 14.7 months in the placebo group), a longer median overall survival (27.3 months versus 23.6 months), and significant improvements in bone pain (54% versus 37%). Side effects, experienced by 86% of nilutamide patients, included hot flashes (28% incidence in treated patients and 22% in placebo patients) and transient night blindness (13% in treated patients and 1% in placebo patients). Less frequent side effects seen in clinical studies were nausea, constipation, and dizziness. Two serious side effects were pulmonary toxicity (2% incidence of interstitial pneumonitis) and hepatotoxicity (1% incidence of hepatitis or marked increases in liver enzymes).

The recommended dosage of nilutamide is six 50-mg tablets once daily for 30 days, followed by three 50 mg tablets once daily, with therapy beginning the same day or the day after surgical castration.

Mitoxantrone

Mitoxantrone (Novantrone) is indicated for hormone-resistant prostate cancer when given in combination with corticosteroids. Available for about 10 years for the treatment of acute non-lymphocytic leukemia, mitoxantrone is also under investigation for metastatic breast cancer and non-Hodgkin’s lymphoma. The drug was approved for prostate cancer on the strength of one open-label Canadian study showing that mitoxantrone plus prednisone significantly reduced bone pain in patients who had failed hormone therapy. The unblinded Canadian study involved 161 patients whose cancer had progressed despite castration and antiandrogen therapy (estrogen, luteinizing-hormone-releasing hormone agonists, cyproterone acetate, or flutamide). Patients were randomized to mitoxantrone 12 mg/m2 IV every three weeks plus 5 mg oral prednisone twice daily, or to prednisone alone. Patients who did not respond to prednisone alone were crossed over to mitoxantrone plus prednisone.

Overall, 38% of patients in the mitoxantrone plus prednisone group reported pain relief (or reduction in analgesic use) compared with 12% of patients on prednisone alone. The duration of pain relief was 33 weeks for the combination and eight weeks for prednisone alone. Also, mitoxantrone delayed progression of the disease (time to progression was 24 weeks compared to 10 weeks for prednisone alone) and reduced prostate specific antigen levels (PSA dropped 75% or more in 27% of patients receiving mitoxantrone compared with 5% of patients on prednisone alone). The most common side effects were nausea, hair loss, fatigue, weight loss and infection, and the most serious side effects were left ventricular dysfunction and myelosuppression. Despite the side effects, mitoxantrone therapy was associated with improvements in the quality of life, both physical and functional.

Buy non prescription drugs: Asacol, Diamox

Related posts:

1. Prostate Cancer: Options in Moderate- and Late-Stage Cancer Buy non prescription drugs: Asacol, Diamox External beam radiation therapy (EBRT) and interstitial implantation (brachytherapy) are the two types of radiation therapy (RT) currently available for treatment of prostate cancer. The course for external beam radiation therapy is four to six weeks and...
2. Liarozole: the Treatment of Recurrent Prostate Cancer Buy non prescription drugs: Asacol, Diamox Each year in the United States, 317,000 cases of prostate cancer are reported, with 41,400 men dying from it. About 50% of patients suffer from metastatic disease when they are diagnosed. These patients are treated with medical...
3. Prostate Cancer: Prevention Buy non prescription drugs: Asacol, Diamox At this time, there is not an approved chemoprevention agent for prostate cancer, though this is an active area of study. Finasteride is a 5a-reductase inhibitor approved for benign prostatic hyperplasia (BPH) and male pattern baldness. Prostate...
4. Prostate Cancer: Options in Therapy for Early-Stage Cancer Buy non prescription drugs: Asacol, Diamox The current treatments for organ-confined prostate cancer are watchful waiting, radical prostatectomy (RP), and radiation therapy (RT). Watchful Waiting: When patients opt to go without treatment and wait until there is observed disease progression, this is termed...
5. Trelstar Depot: Treatment of Advanced Prostate Cancer Buy non prescription drugs: Asacol, Diamox Brand Name:  Trelstar Depot Active Ingredient: triptorelin pamoate Indication: Palliative treatment of advanced prostate cancer in patients in whom orchiectomy or estrogen administration is not indicated or is unacceptable Company Name: Pharmacia & Upjohn Availability: Approved by...